Dayvigo Geriatric (65+) Caregiver Administration Guidance

What Lemborexant Is and Why It Is Used in Older Adults

Lemborexant blocks orexin receptors OX1R and OX2R, which suppresses the wake-promoting signals that keep people with insomnia awake at night. Unlike older sedative-hypnotics such as zolpidem, it does not act on GABA receptors, a mechanism difference that may reduce certain side effects common in frail elderly patients. The FDA approved lemborexant on December 20, 2019, under NDA 211455 for adults with insomnia disorder characterized by difficulty with sleep onset or maintenance. [1]

Why Older Adults Need Special Attention

Adults 65 and older already experience normal age-related changes in sleep architecture, including reduced slow-wave sleep and earlier circadian phase shifts. [2] These changes make chronic insomnia highly prevalent, affecting roughly 30 to 48 percent of older adults by some estimates. [3] At the same time, older adults are more sensitive to CNS-active drugs because of reduced hepatic clearance, lower lean body mass, and a higher baseline fall risk. Every decision about sleep pharmacotherapy in this age group therefore requires careful caregiver support.

The Phase 3 Evidence Base

The SUNRISE 1 trial (N=1,006) compared lemborexant 5 mg and 10 mg against placebo and zolpidem tartrate extended-release 6.25 mg over 1 month. Lemborexant 5 mg reduced subjective sleep onset latency (sSOL) by 18 minutes versus placebo (P<0.001) and showed numerically less next-morning residual sleepiness on the Karolinska Sleepiness Scale compared with zolpidem ER. [4] The SUNRISE 2 trial (N=949) extended treatment to 12 months and showed sustained efficacy with no evidence of tolerance or rebound insomnia on discontinuation. [5] A pre-specified subgroup analysis of participants 65 and older in SUNRISE 2 showed comparable efficacy to the overall population, supporting use without automatic dose reduction by age.

FDA-Approved Dosing for Adults 65 and Older

The FDA-approved starting dose for all adults, including those 65 and older, is 5 mg taken orally once per night. [1] No age-based dose adjustment is required, but prescribers often start at 5 mg in geriatric patients before considering an increase to 10 mg.

When 10 mg May Be Considered

The prescribing information permits escalation to 10 mg if 5 mg is tolerated but does not produce adequate sleep improvement. [1] In clinical practice, many prescribers defer the 10 mg dose in patients older than 75, in those with a documented fall history, or in those taking medications that slow CYP3A metabolism. The decision belongs to the prescribing clinician. Caregivers should not adjust the dose independently.

Hepatic Impairment Adjustments

Older adults disproportionately have mild or moderate hepatic impairment, even without a formal diagnosis. The prescribing information states that lemborexant 5 mg is the maximum recommended dose in patients with moderate hepatic impairment (Child-Pugh B), and the drug is not recommended for patients with severe hepatic impairment (Child-Pugh C). [1] Caregivers managing patients with known liver disease should confirm the correct dose with the prescriber before the first administration.

Step-by-Step Caregiver Administration Instructions

Correct administration reduces the risk of both treatment failure and adverse events. The following sequence is derived from FDA labeling and pharmacokinetic data. [1] [6]

Preparing the Dose

1. Retrieve the lemborexant tablet from its child-resistant container and confirm the correct strength (5 mg tablets are round; 10 mg tablets are oval, per the FDA label).
2. Check the time. Give the tablet within 30 minutes of the patient's intended bedtime, not hours before.
3. Offer a small glass of water. The tablet may be taken with or without food, but avoid giving grapefruit or grapefruit juice within two hours because grapefruit inhibits CYP3A4 and raises lemborexant plasma concentrations. [1]
4. Have the patient swallow the tablet whole. Do not crush or split.

Getting the Patient into Bed

Once the tablet is swallowed, guide the patient directly to bed. Lemborexant's median time to maximum plasma concentration (Tmax) is approximately 1 to 3 hours, but sedation can begin within 30 minutes in some older adults. [6] The patient should not walk to another room, use the stove, or engage in any activity requiring alertness after taking the dose.

Ensure the bedroom path to the bathroom is lit, free of rugs, and has a grab bar or raised toilet seat in place before giving the dose. This preparation takes less than five minutes and prevents most fall injuries.

Confirming the Sleep Window

Ask the patient what time they need to wake up. Count back 7 hours minimum. If the answer gives fewer than 7 hours, delay the dose by 15 to 30 minutes or discuss the schedule with the prescriber. [1] Patients woken before 7 hours have elapsed may have measurable residual impairment affecting balance and reaction time.

Fall Prevention: The Most Critical Caregiver Responsibility

Falls are the leading cause of injury death in adults 65 and older in the United States. The CDC reported approximately 36,000 fall-related deaths in 2020. [7] Any sedative-hypnotic adds to this risk, and lemborexant is no exception.

Residual Morning Sedation in Older Adults

In the SUNRISE 1 trial, next-morning driving simulation performance was measured after lemborexant 10 mg. Driving performance was impaired at 8 hours post-dose for women and was not significantly different from placebo at 8 hours for men, suggesting sex and individual pharmacokinetics matter. [4] Because older adults often have slower drug clearance, residual sedation may last longer than in younger trial participants. [8]

Practically, this means the morning-after transfer (from bed to bathroom, or from bed to breakfast table) carries real risk. Caregivers should be present for the first morning rise after initiating therapy and on any dose increase.

Environmental Modifications Before the First Dose

• Remove loose rugs from the bedroom, hallway, and bathroom.
• Install nightlights at floor level along the path to the bathroom.
• Place a commode or raised toilet seat beside the bed if the bathroom is more than four steps away.
• Confirm bed rails or grab bars are secure.
• Ensure the patient's footwear is non-slip.

These modifications take roughly 20 minutes to implement and should be completed before day one of therapy. [9]

Next-Morning Assessment Checklist

Each morning for at least the first two weeks, caregivers should ask the patient three questions before they stand:

1. "Do you feel dizzy or unsteady?"
2. "Do your legs feel heavy?"
3. "Did you sleepwalk or do anything unusual in the night?"

A positive answer to any of these warrants a call to the prescriber before the next dose.

Drug Interactions Caregivers Must Know

Lemborexant is a CYP3A4 substrate. Drug interactions in this pathway can sharply raise or lower lemborexant exposure, which matters enormously in geriatric polypharmacy. [10]

Strong CYP3A Inhibitors: Do Not Combine

The FDA labeling lists concomitant use of strong CYP3A inhibitors as contraindicated with lemborexant. [1] Common examples in older adults include:

• Clarithromycin (prescribed for respiratory infections)
• Ketoconazole (sometimes used topically or systemically for fungal infections)
• Ritonavir and other HIV protease inhibitors

If any new antibiotic or antifungal is prescribed, caregivers must contact the prescriber immediately to review the lemborexant dose or pause treatment temporarily.

Moderate CYP3A Inhibitors: Use With Caution

Moderate inhibitors such as fluconazole, diltiazem, and erythromycin increase lemborexant exposure to a lesser but still clinically meaningful degree. The prescribing information recommends limiting lemborexant to 5 mg maximum when a moderate CYP3A inhibitor cannot be avoided. [1]

CNS Depressants: Additive Risk

Older adults prescribed opioids, benzodiazepines, muscle relaxants, or first-generation antihistamines face additive CNS depression when lemborexant is added. The American Geriatrics Society's 2023 Beers Criteria warns against routine use of benzodiazepines and hypnotics in older adults precisely because of fall and cognitive impairment risks. [11] Caregivers managing patients on any of these agents should flag the combination for the prescriber.

Alcohol

Lemborexant combined with alcohol accelerates CNS depression onset. Even moderate alcohol consumption the same evening as lemborexant is unsafe. Caregivers should make sure alcohol is not given in any form (including wine with dinner) on nights when lemborexant will be taken.

Swallowing Difficulties and Tube-Fed Patients

Some geriatric patients have dysphagia, making standard tablet administration risky. The FDA label does not authorize crushing or dissolving lemborexant. [1] Crushing an immediate-release coated tablet may alter pharmacokinetics and increase peak concentration unpredictably.

When a Patient Cannot Swallow Tablets

If a patient cannot reliably swallow a whole tablet, caregivers must inform the prescriber before attempting any modification. The prescriber may refer to a speech-language pathologist for dysphagia evaluation or may switch to an alternative sleep agent with a liquid formulation or a dissolvable format. Attempting to crush lemborexant without prescriber guidance is not safe practice.

Enteral (Tube) Feeding

No pharmacokinetic data support administration of lemborexant through a nasogastric or PEG tube. The FDA prescribing information does not address this route. Caregivers of tube-fed patients should raise this question explicitly with the prescriber and pharmacist. [1]

Monitoring for Complex Sleep Behaviors

The FDA added a boxed warning to all Schedule IV sedative-hypnotics in 2019, requiring labeling to describe the risk of complex sleep behaviors, including sleepwalking, sleep-driving, and preparing or eating food while asleep without any memory of the event. [12] This warning applies to lemborexant.

How to Recognize Complex Sleep Behaviors

Caregivers who sleep in the same household have a unique advantage: they can directly observe nighttime activity. Signs to watch for include:

• Finding the patient in a room other than the bedroom in the morning with no memory of going there
• Discovering food preparation evidence (crumbs, open packages) that the patient does not recall
• The patient reporting vivid, disturbing dreams with physical activity

Any such event requires discontinuation of lemborexant and an urgent call to the prescriber. The FDA label states that lemborexant should be discontinued if a complex sleep behavior episode occurs. [1] [12]

Caregiver Reporting to the Prescriber

Document each unusual event in writing with date, time, and description. This record helps the prescriber distinguish complex sleep behavior from nocturnal delirium, REM sleep behavior disorder, or other conditions that require different management. A 2021 pharmacovigilance review in the Journal of Clinical Sleep Medicine found that orexin receptor antagonists, as a class, have a lower reported rate of complex sleep behaviors compared with older sedative-hypnotics, though reporting bias makes direct comparison uncertain. [13]

Cognitive Considerations in Dementia and MCI

Older adults with mild cognitive impairment (MCI) or mild to moderate dementia are frequently prescribed sleep aids because sleep disturbance is nearly universal in these populations. A 2020 randomized trial published in JAMA Network Open (N=128) found that lemborexant 5 mg significantly improved sleep efficiency in patients with Alzheimer's disease dementia compared with placebo over 4 weeks, with a mean increase in sleep efficiency of 4.4 percentage points (P<0.001). [14]

Caregiver Supervision Is Non-Negotiable in Cognitive Impairment

Patients with dementia cannot reliably report adverse effects, including dizziness, confusion, or complex sleep behaviors. Caregivers must actively monitor and may need to be physically present in the room or use a bed sensor alarm to detect nighttime movement. The Alzheimer's Association recommends that all pharmacologic sleep interventions in dementia patients be accompanied by a structured caregiver monitoring plan. [15]

Anticholinergic Load

Many dementia patients are already taking medications with anticholinergic properties, such as oxybutynin for bladder control. The combination of a sedative-hypnotic and a high anticholinergic burden compound confusion risk. The prescribing clinician should calculate the patient's total anticholinergic burden using a validated tool such as the Anticholinergic Cognitive Burden (ACB) scale before adding lemborexant. [16] Caregivers can assist by providing a complete medication list, including over-the-counter antihistamines (e.g., diphenhydramine, found in many "PM" pain products).

Dose Administration in Assisted Living and Memory Care Settings

Caregivers in institutional settings face additional workflow requirements compared with home caregivers. Lemborexant is Schedule IV, which means it must be stored in a locked controlled substance cabinet, documented on a medication administration record (MAR), and wasted if not administered according to facility policy. [17]

Timing Challenges in Shift-Work Settings

Shift handovers often occur at 10 PM or 11 PM. Caregivers must ensure that the nurse or aide responsible for lemborexant administration has received a clear handover that includes the patient's bedtime target, sleep window, and any fall-risk concerns from the prior shift. Missed doses should be documented on the MAR and never doubled the following night. [1]

Documentation Best Practices

Each administration should record:

• Exact time of administration
• Patient's reported pain or discomfort (which may prevent sleep and confound efficacy assessment)
• Whether the patient remained in bed within 15 minutes of administration
• Any morning observations of unusual behavior or difficulty rising

This documentation supports the prescriber's 30-day reassessment, which is standard of care for any newly initiated controlled sleep aid in a geriatric patient. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guidelines for chronic insomnia treatment recommend reassessment no later than 4 weeks after initiation of any pharmacologic agent. [18]

When to Contact the Prescriber or Seek Emergency Care

Caregivers are often the first to notice that something is wrong. The following situations require immediate action.

Call the Prescriber the Same Day

• First occurrence of morning dizziness, unsteady gait, or difficulty waking
• Any new prescription of an antibiotic, antifungal, or antiviral that may inhibit CYP3A
• Persistent next-day sedation lasting past noon after three consecutive nights
• Reports of unusual dreams with physical activity
• Patient refuses the tablet or requests a dose change

Call 911 Immediately

• Patient found unresponsive or difficult to arouse
• Patient found on the floor (fall event), even with no visible injury (internal injury and head trauma must be excluded)
• Chest pain, trouble breathing, or sudden confusion with agitation

The FDA MedWatch program accepts voluntary adverse event reports from caregivers as well as clinicians. Reporting a serious adverse event to MedWatch (1-800-FDA-1088 or online at fda.gov/safety/medwatch) contributes to post-market safety surveillance that protects all future patients. [19]